Pharma Stock Declares 1:1 Bonus Shares & Rs. 1.50 Dividend, Q4 Result Is Out Too; Time To Buy?

Active Pharmaceutical Ingredients (APIs) are the focus of Anuh Pharma Limited, an Indian bulk drugs manufacturing company. It plays a significant role in the manufacturing of expectorants, corticosteroids, anti-bacterials, anti-malarials, anti-TB medicines, and anti-hypertensive pharmaceuticals. A member of the SK Group of Companies is Anuh Pharma. Anuh Pharma is a well-known export company with a robust local market that serves a number of nations in South America, Africa, and Europe. The headquarters of Anuh Pharma are situated in Mumbai, Maharashtra, India.

Anuh Pharma Bonus Shares

The Board of Directors considered and approved "Issue of Bonus Equity Shares in the ratio 1:1, i.e., 1 (One) equity shares of Rs 5.00/- each for every 1 (One) full paid-up equity share of Rs 5.00/- each held by the Shareholders as on the Record Date. The issue of Bonus shares is subject to shareholders' approval via Postal Ballot. The Record Date will be announced in due course," said Anuh Pharma in a stock exchange filing.

Anuh Pharma Dividend

The Board of Directors considered and approved "Recommendation of Dividend of Rs. 1.50/- per Equity share on post-bonus share capital, amounting to a 30% payout on the face value of Rs. 5/- each for the Financial Year ended 31st March, 2025. The proposed dividend is subject to Shareholder's approval at the ensuing Annual General Meeting (AGM) of the Company. Bonus Shares will also be entitled to proposed final dividend of Rs. 1.50/- per equity share," informed Anuh Pharma to stock exchanges.

The Register of Members and Share Transfer Books of the company will remain closed from 16th August, 2024 to 22nd August, 2025 (both days inclusive) for the purpose of Annual General Meeting and for the purpose of dividend, if approved by members, according to the company.

Anuh Pharma Q4 Results

Anuh Pharma's net profit plummeted 18.88% to Rs 12.46 crore in the March 2025 quarter from Rs 15.36 crore in the March 2024 quarter. Compared to Rs 163.89 crore in the year-ago quarter, which ended in March 2024, sales increased 20.90% to Rs 198.14 crore in the quarter that concluded in March 2025. EBITDA decreased 8.98% from Rs. 22.05 crore in Q4FY24 to Rs. 20.07 crore in Q4FY25.

In the year ending in March 2025, net profit declined 21.16% to Rs 47.35 crore, compared to Rs 60.06 crore in the year ending in March 2024. Compared to Rs 647.00 crore in FY24, sales increased by 2.24% to Rs 661.51 crore in the entire fiscal year ending in FY25.

Anuh Pharma Share Price Target

"Anuh Pharma stock price is bullish but also overbought on the Daily charts with strong support at 180. A Daily close above resistance of 217 could lead to a target of 244 in the near term," commented A R Ramachandran, independent research analyst.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.